PTC TherapeuticsPTCT
PTCT
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
229% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 17
20% more capital invested
Capital invested by funds: $2.93B [Q3] → $3.51B (+$582M) [Q4]
18% more funds holding
Funds holding: 201 [Q3] → 237 (+36) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 75
2.0% less ownership
Funds ownership: 102.75% [Q3] → 100.75% (-2.0%) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
62% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $28.2M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
5%
downside
Avg. target
$68
43%
upside
High target
$113
138%
upside
7 analyst ratings
4 positive
57%
2 neutral
29%
1 negative
14%
JP Morgan Eric Joseph 30% 1-year accuracy 8 / 27 met price target | 58%upside $75 | Overweight Maintained | 31 Mar 2025 |
B of A Securities Tazeen Ahmad 25% 1-year accuracy 8 / 32 met price target | 16%upside $55 | Neutral Upgraded | 11 Mar 2025 |
Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target | 16%upside $55 | Sector Perform Initiated | 7 Mar 2025 |
Morgan Stanley Jeffrey Hung 8% 1-year accuracy 2 / 26 met price target | 48%upside $70 | Overweight Assumed | 7 Mar 2025 |
RBC Capital Brian Abrahams 3% 1-year accuracy 2 / 66 met price target | 33%upside $63 | Outperform Maintained | 18 Feb 2025 |
Financial journalist opinion
Based on 8 articles about PTCT published over the past 30 days
Neutral
Zacks Investment Research
2 days ago
PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
2 days ago
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
WARREN, N.J. , April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m.
Negative
CNBC Television
2 weeks ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Neutral
PRNewsWire
3 weeks ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees.
Negative
Market Watch
3 weeks ago
PTC Therapeutics Shares Fall After EU Drops Translarna Authorization
Shares of PTC Therapeutics fell after the company said regulators for the European Union won't renew authorization for its Translarna treatment for nonsense mutation Duchenne muscular dystrophy.
Negative
Reuters
3 weeks ago
PTC Therapeutics says European Commission will remove muscle disorder drug
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.
Neutral
PRNewsWire
3 weeks ago
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy.
Neutral
PRNewsWire
4 weeks ago
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes — WARREN, N.J. , March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
Positive
Seeking Alpha
1 month ago
PTC Therapeutics: Upside In Rare Disease Innovation
PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market.
Neutral
Seeking Alpha
1 month ago
PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Tiago Fauth - Wells Fargo Eli Merle - UBS Gena Wang - Barclays Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Tazeen Ahmad - Bank of America Securities David Lebowitz - Citi Operator Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™